DHR vs LLY: Which Is the Better Buy?
Side-by-side comparison of Danaher Corporation and Eli Lilly and Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
Danaher Corporation · Healthcare
$177.17
+8.9% upside to fair value
Grade B
High Quality
VS
Eli Lilly and Company · Healthcare
$1,098.13
+16.7% upside to fair value
Grade B
High Quality
QuantHub Verdict
LLY has more upside to fair value
(+16.7%).
DHR trades at a lower forward P/E
(34.1x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DHR |
LLY |
| Current Price |
$177.17 |
$1,098.13 |
| Fair Value Estimate |
$192.90 |
$1,281.02 |
| Upside to Fair Value |
+8.9%
|
+16.7%
|
| Market Cap |
$125.4B |
$1,034.2B |
| Forward P/E |
34.1x
|
38.9x
|
| EV / EBITDA |
20.8x
|
32.0x
|
| Price / Sales |
5.1x
|
14.3x
|
| Price / FCF |
23.7x
|
76.2x
|
| Revenue Growth YoY |
+3.7%
|
+55.5%
|
| Gross Margin |
60.7%
|
83.5%
|
| Operating Margin |
21.0%
|
45.9%
|
| Return on Equity |
7.1%
|
101.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.22%
|
1.31%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
Danaher Corporation operates in the healthcare sector, specializing in medical diagnostics and research tools through three balanced platforms: Biotechnology, Life Sciences, and Diagnostics. The company benefits from a durable competitive moat supported by the Danaher Business System, disciplined capital allocation, and a platform-centric organizational structure. Despite modest revenue growth of…
Eli Lilly and Company is a leading healthcare firm specializing in drug manufacturing with a strong competitive moat in GLP-1 diabetes and obesity treatments as well as biologics manufacturing. The company is led by experienced internal management with a proven capital allocation track record. Its revenue growth is exceptionally strong, driven by its cardiometabolic franchise which accounted for …
Accumulation Zones
| Metric |
DHR |
LLY |
| Zone Low |
$144.68 |
$960.76 |
| Zone High |
$163.97 |
$1,088.87 |
| In Buy Zone? |
No
|
No
|